A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Iizumi Sakura0 个研究点目标入组 527 人开始时间: 2022年4月15日最近更新: 2024年5月27日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 527

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 <= 100age old（—）
性别: All

入选标准

•1. Participant has provided informed consent/assent before initiation of any study specific activities/procedures.
•2. Age >= 18 years.
•3. Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a, 1j, 1k, and 2a only) and/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b).
•4. Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation.
•5. Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to investigational product.
•6. Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
•7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
•8. Adequate hematopoietic function per local laboratory.
•9. Adequate renal function per local laboratory.
•10. Adequate glucose control per local laboratory (Part 1 only).
•11. Adequate liver function per local laboratory.
•12. Adequate coagulation parameters.
•13. Adequate pulmonary function.
•14. Adequate cardiac function.
•15. Minimum life expectancy of 12 weeks as per investigator judgement.
•16. A total of 25 slides of archived tumor tissue (formalin-fixed, paraffin-embedded [FFPE] sample collected within 5 years) or an archival block must be available.
•17. For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo tumor biopsy.
•18. For Part 1abackfill: Must be willing to undergo tumor biopsy, before start of treatment (archival sample acceptable if obtained with 6 months of enrollment and subject has not received any other treatment since sample was obtained) and while on treatment.
•19. Part 1i: Enrollment criteria for Part 1i are to match the criteria of the expansion arm from which the indication was selected.
•20. For DSPS study (Part 1j): Must be willing to participate in DSPS substudy (US sites only).
•Food Effect Substudy (Part 1k): Specific Inclusion Criteria
•21. Subject able and willing to eat a standardized high-fat, high-caloric meal
•22. Subject able and willing to fast for >= 6 hours

排除标准

•1. Spinal cord compression or untreated brain metastases or leptomeningeal disease.
•2. History of other malignancy within the past 2 years.
•3. Any evidence of current interstitial lung disease
•4. Active infection.
•5. Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection.
•6. History of arterial thrombosis.
•7. Myocardial infarction and/or symptomatic congestive heart failure.
•8. Gastrointestinal tract disease.
•9. History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
•10. History of solid organ transplant.
•11. Diagnosis of Congenital Short QT Syndrome.
•12. Major surgery
•13. Anti-tumor therapy within 28 days of study day 1, unless anti-tumor therapy is a therapy with 5 times the half-life being shorter than 28 days
•14. Prior treatment with an methionine adenosyltransferase 2a (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
•15. Prior treatment with docetaxel (Part 2 only)
•16. Prior irradiation to >25% of the bone marrow.
•17. Therapeutic or palliative radiation therapy within 2 weeks of study day 1.
•18. Live vaccine therapy within 4 weeks before study drug administration.
•19. Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
•20. Use of prescription medications that are known strong inducers of cytochrome P450 3A4 (CYP3A4) within 14 days or 5half-lives (whichever is longer) before study day 1
•21.Unresolved toxicity from prior anti-cancer therapy.
•22. Currently receiving treatment in another investigational device or drug study.
•23. Known positive test for Human Immunodeficiency Virus (HIV).
•24. Positive hepatitis B surface antigen
•25. positive hepatitis C virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)
•26. Female participants of childbearing potential unwilling to use protocol specified method of contraception.

研究者

发起方

Iizumi Sakura

相似试验

招募中

1 期

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

JPRN-jRCT2041220013Kaneda Hirokazu80

进行中（未招募）

1 期

Study Assessing the Safety, Tolerability and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic fibrosis

EUCTR2017-003319-21-GBProteostasis Therapeutics, Inc.240

进行中（未招募）

1 期

EUCTR2017-003319-21-BEProteostasis Therapeutics, Inc.240

进行中（未招募）

1 期

Study Assessing the Safety, Tolerability and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic FibrosisCystic fibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2017-003319-21-DEProteostasis Therapeutics, Inc.240

进行中（未招募）

1 期

A Phase 1/2 Study of AMG 193 in Combination with IDE397 in Subjects with Advanced MTAP-null Solid Tumors

CTIS2023-504364-42-00Amgen Inc.184